Literature DB >> 18773143

The biological activity of G-quadruplex DNA binding papaverine-derived ligand in breast cancer cells.

Blazej Rubis1, Mariusz Kaczmarek, Natalia Szymanowska, Elzbieta Galezowska, Andrzej Czyrski, Bernard Juskowiak, Tadeusz Hermann, Maria Rybczynska.   

Abstract

It was shown previously that the papaverine oxidation products 6a,12a-diazadibenzo-[a,g]fluorenylium derivative (ligand 1) and 2,3,9,10-tetramethoxy-12-oxo-12H-indolo[2,1-a]isoquinolinium chloride (ligand 2) bind to guanine-quadruplexes (G4) of single stranded G-rich 3'-overhangs of mammalian telomeric DNA. Here we show the biological activity of ligand 1. This compound exhibit antiproliferative activity in MCF-7 cells (IC(50) for ligand 1 = 14.16 +/- 0.01 microM, 24 h, 1.158 +/- 0.056 microM, 72 h. PCNA levels were not altered after treatment of MCF-7 cells with concentrations of ligand 1 which, however, led to alterations in the cell cycle. 5 and 10 microM of the ligand 1 arrested cells in the G0/G1 phase of the cell cycle and this led to a decrease of cells in the S phase. Intracellular accumulation of ligand 1 was observed even after a cell passage and medium exchange in fluorescence microscopy while low concentrations of ligand 1 (0.001 to 0.1 microM) inhibited telomerase activity as shown by TRAP assay.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18773143     DOI: 10.1007/s10637-008-9173-9

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  37 in total

Review 1.  G-Quadruplex DNA as a target for drug design.

Authors:  S M Kerwin
Journal:  Curr Pharm Des       Date:  2000-03       Impact factor: 3.116

2.  Inhibition of telomerase by G-quartet DNA structures.

Authors:  A M Zahler; J R Williamson; T R Cech; D M Prescott
Journal:  Nature       Date:  1991-04-25       Impact factor: 49.962

Review 3.  Cell cycle progression: new therapeutic target for vascular proliferative disease.

Authors:  R C Braun-Dullaeus; M J Mann; V J Dzau
Journal:  Circulation       Date:  1998-07-07       Impact factor: 29.690

Review 4.  Telomerase therapeutics for cancer: challenges and new directions.

Authors:  Jerry W Shay; Woodring E Wright
Journal:  Nat Rev Drug Discov       Date:  2006-06-09       Impact factor: 84.694

5.  Spectroscopic recognition of guanine dimeric hairpin quadruplexes by a carbocyanine dye.

Authors:  Q Chen; I D Kuntz; R H Shafer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

6.  Apoptosis related to telomere instability and cell cycle alterations in human glioma cells treated by new highly selective G-quadruplex ligands.

Authors:  Gaëlle Pennarun; Christine Granotier; Laurent R Gauthier; Dennis Gomez; Françoise Hoffschir; Eliane Mandine; Jean-François Riou; Jean-Louis Mergny; Patrick Mailliet; François D Boussin
Journal:  Oncogene       Date:  2005-04-21       Impact factor: 9.867

7.  A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity.

Authors:  Sharon M Gowan; John R Harrison; Lisa Patterson; Melanie Valenti; Martin A Read; Stephen Neidle; Lloyd R Kelland
Journal:  Mol Pharmacol       Date:  2002-05       Impact factor: 4.436

8.  A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cells.

Authors:  Christopher M Incles; Christoph M Schultes; Helena Kempski; Heike Koehler; Lloyd R Kelland; Stephen Neidle
Journal:  Mol Cancer Ther       Date:  2004-10       Impact factor: 6.261

9.  P-glycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth.

Authors:  M Drozdzik; K Mysliwiec; M Lewinska-Chelstowska; J Banach; A Drozdzik; J Grabarek
Journal:  J Clin Periodontol       Date:  2004-09       Impact factor: 8.728

10.  A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia.

Authors:  M Sumi; T Tauchi; G Sashida; A Nakajima; A Gotoh; K Shin-Ya; J H Ohyashiki; K Ohyashiki
Journal:  Int J Oncol       Date:  2004-06       Impact factor: 5.650

View more
  4 in total

1.  Repositioning antispasmodic drug Papaverine for the treatment of chronic myeloid leukemia.

Authors:  Phani Krishna Parcha; Sailu Sarvagalla; Cheemala Ashok; S J Sudharshan; Madhu Dyavaiah; Mohane Selvaraj Coumar; Baskaran Rajasekaran
Journal:  Pharmacol Rep       Date:  2021-01-03       Impact factor: 3.024

2.  Non-addictive opium alkaloids selectively induce apoptosis in cancer cells compared to normal cells.

Authors:  Monireh Afzali; Padideh Ghaeli; Mahnaz Khanavi; Maliheh Parsa; Hamed Montazeri; Mohammad Hossein Ghahremani; Seyed Nasser Ostad
Journal:  Daru       Date:  2015-02-20       Impact factor: 3.117

Review 3.  Telomerase as a useful target in cancer fighting-the breast cancer case.

Authors:  Hanna Holysz; Natalia Lipinska; Anna Paszel-Jaworska; Blazej Rubis
Journal:  Tumour Biol       Date:  2013-04-05

4.  Mucoadhesive Chitosan Delivery System with Chelidonii Herba Lyophilized Extract as a Promising Strategy for Vaginitis Treatment.

Authors:  Magdalena Paczkowska; Justyna Chanaj-Kaczmarek; Aleksandra Romaniuk-Drapała; Błażej Rubiś; Daria Szymanowska; Joanna Kobus-Cisowska; Emilia Szymańska; Katarzyna Winnicka; Judyta Cielecka-Piontek
Journal:  J Clin Med       Date:  2020-04-22       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.